. . . . "Idarubicin has antimitotic and cytotoxic activity through a number of proposed mechanisms of action: Idarubicin forms complexes with DNA by intercalation between base pairs, and it inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes."@en . "Idarubicina"@en . " "@en . "Idarubicin"@en . . . "(1S,3S)-3-Acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside"@en . . . "Marco Villa, Roberto Arosio, Roberta Fretta, Nicola Diulgheroff, \"Synthesis of idarubicin aglycone.\" U.S. Patent US20060047108, issued March 02, 2006."@en . "An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. [PubChem]"@en . . "Idarubicine"@en . "Bacteria"@en . . . . . . . . . . . . . . . . . . . "The drug is eliminated predominately by biliary and to a lesser extent by renal excretion, mostly in the form of idarubicinol."@en . "97%"@en . . . . . . "approved"@en . . . . . . . "For the treatment of acute myeloid leukemia (AML) in adults. This includes French-American-British (FAB) classifications M1 through M7."@en . "22 hours"@en . . "4-Demethoxydaunomycin"@en . "5,12-Naphthacenedione, 9-acetyl-7-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-, (7S-cis)-"@en . . "Humans and other mammals"@en . . "4-Demethoxydaunorubicin"@en . . . . . . . . . "58957-92-9"@en . " "@en . . . . . "Idarubicinum"@en . . . .